Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Boquet I, Kassambara A, Lui A, Tanner A, Latil M, Lovera Y, Arnoux F, Hermitte F, Galon J, Catteau A. Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring. Cancers (Basel) 2022;14:cancers14051170. [PMID: 35267475 PMCID: PMC8909354 DOI: 10.3390/cancers14051170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 02/15/2022] [Accepted: 02/18/2022] [Indexed: 12/12/2022] Open

For:	Boquet I, Kassambara A, Lui A, Tanner A, Latil M, Lovera Y, Arnoux F, Hermitte F, Galon J, Catteau A. Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring. Cancers (Basel) 2022;14:cancers14051170. [PMID: 35267475 PMCID: PMC8909354 DOI: 10.3390/cancers14051170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 02/15/2022] [Accepted: 02/18/2022] [Indexed: 12/12/2022] Open

Number

Cited by Other Article(s)

Hijazi A, Galon J. Principles of risk assessment in colon cancer: immunity is key. Oncoimmunology 2024;13:2347441. [PMID: 38694625 PMCID: PMC11062361 DOI: 10.1080/2162402x.2024.2347441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 04/16/2024] [Indexed: 05/04/2024] Open

Abstract

In clinical practice, the administration of adjuvant chemotherapy (ACT) following tumor surgical resection raises a critical dilemma for stage II colon cancer (CC) patients. The prognostic features used to identify high-risk CC patients rely on the pathological assessment of tumor cells. Currently, these factors are considered for stratifying patients who may benefit from ACT at early CC stages. However, the extent to which these factors predict clinical outcomes (i.e. recurrence, survival) remains highly controversial, also uncertainty persists regarding patients' response to treatment, necessitating further investigation. Therefore, an imperious need is to explore novel biomarkers that can reliably stratify patients at risk, to optimize adjuvant treatment decisions. Recently, we evaluated the prognostic and predictive value of Immunoscore (IS), an immune digital-pathology assay, in stage II CC patients. IS emerged as the sole significant parameter for predicting disease-free survival (DFS) in high-risk patients. Moreover, IS effectively stratified patients who would benefit most from ACT based on their risk of recurrence, thus predicting their outcomes. Notably, our findings revealed that digital IS outperformed the visual quantitative assessment of the immune response conducted by expert pathologists. The latest edition of the WHO classification for digestive tumor has introduced the evaluation of the immune response, as assessed by IS, as desirable and essential diagnostic criterion. This supports the revision of current cancer guidelines and strongly recommends the implementation of IS into clinical practice as a patient stratification tool, to guide CC treatment decisions. This approach may provide appropriate personalized therapeutic decisions that could critically impact early-stage CC patient care.

Collapse

Hijazi A, Bifulco C, Baldin P, Galon J. Digital Pathology for Better Clinical Practice. Cancers (Basel) 2024;16:1686. [PMID: 38730638 PMCID: PMC11083211 DOI: 10.3390/cancers16091686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 04/24/2024] [Accepted: 04/25/2024] [Indexed: 05/13/2024] Open

Abstract

(1) Background: Digital pathology (DP) is transforming the landscape of clinical practice, offering a revolutionary approach to traditional pathology analysis and diagnosis. (2) Methods: This innovative technology involves the digitization of traditional glass slides which enables pathologists to access, analyze, and share high-resolution whole-slide images (WSI) of tissue specimens in a digital format. By integrating cutting-edge imaging technology with advanced software, DP promises to enhance clinical practice in numerous ways. DP not only improves quality assurance and standardization but also allows remote collaboration among experts for a more accurate diagnosis. Artificial intelligence (AI) in pathology significantly improves cancer diagnosis, classification, and prognosis by automating various tasks. It also enhances the spatial analysis of tumor microenvironment (TME) and enables the discovery of new biomarkers, advancing their translation for therapeutic applications. (3) Results: The AI-driven immune assays, Immunoscore (IS) and Immunoscore-Immune Checkpoint (IS-IC), have emerged as powerful tools for improving cancer diagnosis, prognosis, and treatment selection by assessing the tumor immune contexture in cancer patients. Digital IS quantitative assessment performed on hematoxylin-eosin (H&E) and CD3+/CD8+ stained slides from colon cancer patients has proven to be more reproducible, concordant, and reliable than expert pathologists' evaluation of immune response. Outperforming traditional staging systems, IS demonstrated robust potential to enhance treatment efficiency in clinical practice, ultimately advancing cancer patient care. Certainly, addressing the challenges DP has encountered is essential to ensure its successful integration into clinical guidelines and its implementation into clinical use. (4) Conclusion: The ongoing progress in DP holds the potential to revolutionize pathology practices, emphasizing the need to incorporate powerful AI technologies, including IS, into clinical settings to enhance personalized cancer therapy.

Collapse

Kuznetsova O, Fedyanin M, Zavalishina L, Moskvina L, Kuznetsova O, Lebedeva A, Tryakin A, Kireeva G, Borshchev G, Tjulandin S, Ignatova E. Prognostic and predictive role of immune microenvironment in colorectal cancer. World J Gastrointest Oncol 2024;16:643-652. [PMID: 38577454 PMCID: PMC10989368 DOI: 10.4251/wjgo.v16.i3.643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 12/20/2023] [Accepted: 01/22/2024] [Indexed: 03/12/2024] Open

Willis J, Anders RA, Torigoe T, Hirohashi Y, Bifulco C, Zlobec I, Mlecnik B, Demaria S, Choi WT, Dundr P, Tatangelo F, Di Mauro A, Baldin P, Bindea G, Marliot F, Haicheur N, Fredriksen T, Kirilovsky A, Buttard B, Vasaturo A, Lafontaine L, Maby P, El Sissy C, Hijazi A, Majdi A, Lagorce C, Berger A, Van den Eynde M, Pagès F, Lugli A, Galon J. Multi-Institutional Evaluation of Pathologists' Assessment Compared to Immunoscore. Cancers (Basel) 2023;15:4045. [PMID: 37627073 PMCID: PMC10452341 DOI: 10.3390/cancers15164045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 07/31/2023] [Accepted: 08/08/2023] [Indexed: 08/27/2023] Open

Affiliation(s)

Joseph Willis Department of Pathology, UH Cleveland Medical Center, Cleveland, OH 44106, USA;
Robert A. Anders Pathology Department, John Hopkins, Baltimore, MD 21287, USA;
Toshihiko Torigoe Department of Pathology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan; (T.T.); (Y.H.)
Yoshihiko Hirohashi Department of Pathology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan; (T.T.); (Y.H.)
Carlo Bifulco Department of Pathology and Molecular Genomics, Providence Portland Medical Center, Portland, OR 97213, USA;
Inti Zlobec Institute of Pathology, University of Bern, 3008 Bern, Switzerland; (I.Z.); (A.L.)
Bernhard Mlecnik INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Inovarion, 75005 Paris, France
Sandra Demaria Department of Pathology, Weill Cornell Medicine, New York, NY 10021, USA;
Won-Tak Choi Department of Pathology, University of California, San Francisco, CA 94143, USA;
Pavel Dundr Institute of Pathology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 12808 Prague, Czech Republic;
Fabiana Tatangelo Department of Pathology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy; (F.T.); (A.D.M.)
Annabella Di Mauro Department of Pathology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy; (F.T.); (A.D.M.)
Pamela Baldin Department of Pathology, Cliniques Universitaires St-Luc, Institut de Recherche Clinique et Experimentale (Pole GAEN), Université Catholique de Louvain, 1348 Brussels, Belgium;
Gabriela Bindea INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Florence Marliot INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Nacilla Haicheur INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Tessa Fredriksen INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Amos Kirilovsky INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Bénédicte Buttard INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Angela Vasaturo INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Lucie Lafontaine INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Pauline Maby INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Carine El Sissy INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Assia Hijazi INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Amine Majdi INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France
Christine Lagorce INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Department of Pathology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Anne Berger INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Digestive Surgery Department, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Marc Van den Eynde Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires St-Luc, Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, 1030 Brussels, Belgium;
Franck Pagès INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, 75015 Paris, France
Alessandro Lugli Institute of Pathology, University of Bern, 3008 Bern, Switzerland; (I.Z.); (A.L.)
Jérôme Galon INSERM, Laboratory of Integrative Cancer Immunology, 75006 Paris, France; (B.M.); (G.B.); (F.M.); (N.H.); (T.F.); (A.K.); (B.B.); (A.V.); (L.L.); (P.M.); (C.E.S.); (A.H.); (A.M.); (C.L.); (A.B.); (F.P.) Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, 75006 Paris, France Equipe Labellisée Ligue Contre le Cancer, 75006 Paris, France

Collapse

Su X, Brassard A, Bartolomucci A, Dhoparee‐Doomah I, Qiu Q, Tsering T, Rohanizadeh R, Koufos O, Giannias B, Bourdeau F, Feng L, Messina‐Pacheco J, Leo S, Sangwan V, Quail D, Tankel J, Spicer J, Burnier JV, Bailey SD, Ferri L, Cools‐Lartigue J. Tumour extracellular vesicles induce neutrophil extracellular traps to promote lymph node metastasis. J Extracell Vesicles 2023;12:e12341. [PMID: 37563798 PMCID: PMC10415595 DOI: 10.1002/jev2.12341] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 06/15/2023] [Indexed: 08/12/2023] Open

Affiliation(s)

Xin Su Department of Experimental SurgeryMcGill UniversityMontrealQuebecCanada Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of PathologyMcGill UniversityMontrealQuebecCanada
Ariane Brassard Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of Microbiology and ImmunologyMcGill UniversityMontrealQuebecCanada
Alexandra Bartolomucci Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of PathologyMcGill UniversityMontrealQuebecCanada
Iqraa Dhoparee‐Doomah Department of Experimental SurgeryMcGill UniversityMontrealQuebecCanada Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Qian Qiu Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Thupten Tsering Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of PathologyMcGill UniversityMontrealQuebecCanada
Ramin Rohanizadeh Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Olivia Koufos Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Betty Giannias Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
France Bourdeau Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Lixuan Feng Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of Microbiology and ImmunologyMcGill UniversityMontrealQuebecCanada
Julia Messina‐Pacheco Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of PathologyMcGill UniversityMontrealQuebecCanada
Sabrina Leo Department of Experimental SurgeryMcGill UniversityMontrealQuebecCanada Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Veena Sangwan Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Daniela Quail The Rosalind and Morris Goodman Cancer InstituteMcGill UniversityMontrealQuebecCanada
James Tankel Division of Thoracic and Upper Gastrointestinal SurgeryMcGill UniversityMontrealQuebecCanada
Jonathan Spicer Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Division of Thoracic and Upper Gastrointestinal SurgeryMcGill UniversityMontrealQuebecCanada
Julia Valdemarin Burnier Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Department of PathologyMcGill UniversityMontrealQuebecCanada
Swneke Donovan Bailey Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada
Lorenzo Ferri Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Division of Thoracic and Upper Gastrointestinal SurgeryMcGill UniversityMontrealQuebecCanada
Jonathan Cools‐Lartigue Cancer Research ProgramResearch Institute of McGill University Health CenterMontrealQuebecCanada Division of Thoracic and Upper Gastrointestinal SurgeryMcGill UniversityMontrealQuebecCanada

Collapse

Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, Ugolini C, Proietti A, Conca V, Kassambara A, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, Tamburini E, Poma AM, Fieschi J, Fontanini G, Masi G, Galon J, Cremolini C. Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. J Immunother Cancer 2023;11:jitc-2022-006633. [PMID: 37085190 PMCID: PMC10124320 DOI: 10.1136/jitc-2022-006633] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/02/2023] [Indexed: 04/23/2023] Open

Abstract

BACKGROUND

Tumor immune cells influence the efficacy of immune-checkpoint inhibitors (ICIs) and many efforts aim at identifying features of tumor immune microenvironment able to predict benefit from ICIs in proficient mismatch repair (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

METHODS

We characterized tumor immune cell infiltrate, by assessing tumor-infiltrating lymphocytes (TILs), Immunoscore, Immunoscore-IC, and programmed death ligand-1 (PD-L1) expression in tumor samples of patients with mCRC enrolled in the AtezoTRIBE study, a phase II randomized trial comparing FOLFOXIRI/bevacizumab/atezolizumab to FOLFOXIRI/bevacizumab, with the aim of evaluating the prognostic and predictive value of these features.

RESULTS

Out of 218 patients enrolled, 181 (83%), 77 (35%), 157 (72%) and 162 (74%) specimens were successfully tested for TILs, Immunoscore, Immunoscore-IC and PD-L1 expression, respectively, and 69 (38%), 45 (58%), 50 (32%) and 21 (13%) tumors were classified as TILs-high, Immunoscore-high, Immunoscore-IC-high and PD-L1-high, respectively. A poor agreement was observed between TILs and Immunoscore or Immunoscore-IC (K of Cohen <0.20). In the pMMR population, longer progression-free survival (PFS) was reported for Immunoscore-high and Immunoscore-IC-high groups compared with Immunoscore-low (16.4 vs 12.2 months; HR: 0.55, 95% CI: 0.30 to 0.99; p=0.049) and Immunoscore-IC-low (14.8 vs 11.5 months; HR: 0.55, 95% CI: 0.35 to 0.85; p=0.007), respectively, with a significant interaction effect between treatment arms and Immunoscore-IC (p for interaction: 0.006) and a trend for Immunoscore (p for interaction: 0.13). No PFS difference was shown according to TILs and PD-L1 expression. Consistent results were reported in the overall population.

CONCLUSIONS

The digital evaluation of tumor immune cell infiltrate by means of Immunoscore-IC or Immunoscore identifies the subset of patients with pMMR mCRC achieving more benefit from the addition of the anti-PD-L1 to the upfront treatment. Immunoscore-IC stands as the most promising predictor of benefit from ICIs.

Collapse

Affiliation(s)

Roberto Moretto Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Daniele Rossini Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy
Aurélie Catteau Veracyte, Marseille, France
Carlotta Antoniotti Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy
Mirella Giordano Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy
Alessandra Boccaccino Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy
Clara Ugolini Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
Agnese Proietti Unit of Pathological Anatomy 3, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Veronica Conca Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy
Alboukadel Kassambara Veracyte, Marseille, France
Filippo Pietrantonio Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Lisa Salvatore Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy Oncologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy
Sara Lonardi Medical Oncology 3, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Stefano Tamberi Oncology Unit, Ravenna Hospital, AUSL Romagna, Ravenna, Italy
Emiliano Tamburini Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy
Anello Marcello Poma Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
Jacques Fieschi Veracyte, Marseille, France
Gabriella Fontanini Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
Gianluca Masi Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy
Jérôme Galon INSERM, Laboratory of Integrative Cancer Immunology, Paris, F-75006, France Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Paris, France Equipe Labellisée Ligue Contre le Cancer, Paris, France
Chiara Cremolini Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy

Collapse

Atreya I, Neurath MF. How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes. Biomedicines 2022;10:biomedicines10112940. [PMID: 36428508 PMCID: PMC9687992 DOI: 10.3390/biomedicines10112940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Revised: 11/10/2022] [Accepted: 11/11/2022] [Indexed: 11/17/2022] Open

Chen P, Zhang J, Wu J. Artificial Intelligence in Digital Pathology to Advance Cancer Immunotherapy. 21ST CENTURY PATHOLOGY 2022;2:120. [PMID: 36282981 PMCID: PMC9578679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]